Aspirin (Low-dose)

Treatment for Coronary Artery Disease

Typical Dosage: 75-100mg daily

Effectiveness
80%
Safety Score
80%
Clinical Trials
66
Participants
300K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
80
DangerousModerateSafe
Treatment Details
Dosage Range
75-100mg daily
Time to Effect
immediate antiplatelet effect, clinical benefit over months-years
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
80(Treat 80 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
300(Treat 300 patients to see 1 additional serious adverse event)
Confidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15
Monitoring:$20
Side Effect Mgmt:$30
Total Annual:$65
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$500/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$433
Comparison vs No Treatment
Cost Difference
$-65/year
Less expensive
QALY Difference
+0.08 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Aspirin (Low-dose) Outcomes

for Coronary Artery Disease

Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+15%
Common Side Effects
Gastrointestinal bleeding
+1.5%
Dyspepsia
+5%
Hemorrhagic stroke
+0.05%

Sources:

nih.gov
researchgate.net
ahajournals.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
5 active trials recruiting for Aspirin (Low-dose) in Coronary Artery Disease

Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)

NCT07195149RECRUITINGPHASE3
View Study
1.7K participants
INTERVENTIONAL
Bialystok, Poland +17 more
Started: Nov 25, 2025

One-Month DAPT in CABG Patients

NCT05997693RECRUITINGPHASE3
View Study
700 participants
INTERVENTIONAL
Englewood, United States +21 more
Started: Aug 15, 2024

Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease

NCT06541691RECRUITINGNA
View Study
3K participants
INTERVENTIONAL
Tehran, Iran
Started: Mar 6, 2024

Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial

NCT07524335NOT YET RECRUITINGPHASE3
View Study
48 participants
INTERVENTIONAL
Montreal, Canada
Started: May 1, 2026

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

NCT06228456RECRUITINGPHASE4
View Study
50 participants
INTERVENTIONAL
Jacksonville, United States
Started: Apr 1, 2024
Completed Clinical Trials
7 completed trials for Aspirin (Low-dose) in Coronary Artery Disease

Effects of Low Dose Aspirin Pre-treatment on Platelet Activation Undergoing Off-pump Coronary Artery Bypass Surgery

NCT02209909COMPLETEDNA
View Study
48 participants
INTERVENTIONAL
Seoul, South Korea
Started: Jul 1, 2014

Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel

NCT02567461COMPLETEDPHASE4
View Study
80 participants
INTERVENTIONAL
Jacksonville, United States
Started: Mar 1, 2016

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

NCT04006288COMPLETEDPHASE4
View Study
90 participants
INTERVENTIONAL
Jacksonville, United States
Started: Sep 6, 2019

Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)

NCT01212302COMPLETEDNA
View Study
500 participants
INTERVENTIONAL
Bochum, Germany
Started: Oct 1, 2008

Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

NCT03718429COMPLETEDPHASE4
View Study
86 participants
INTERVENTIONAL
Jacksonville, United States +1 more
Started: Jan 14, 2019

Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation

NCT05797376COMPLETEDPHASE4
View Study
92 participants
INTERVENTIONAL
Seoul, South Korea
Started: Aug 24, 2021

Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk

NCT04753372COMPLETED
View Study
645 participants
OBSERVATIONAL
's-Hertogenbosch, Netherlands +11 more
Started: Dec 21, 2020
Showing 20 of 67 total trials